Ovarian Cancer

Latest News
May 27th 2025

Ovarian Cancer Survival Gaps Persist Across Racial, Ethnic Groups

May 18th 2025

Advances in Ovarian Cancer: Using Genomics and Optimizing Maintenance Therapy

May 16th 2025

Access to Minimally Invasive Surgery for Advanced Ovarian Cancer Varies Widely by Facility

May 13th 2025

Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer

May 11th 2025

Global Analysis Sheds Light on Women’s Cancer Trends

Ovarian Cancer Guideline Updates 2024

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.
Video Interviews
View All
June 5th 2025

ROSELLA Trial Offers New Insight Into Global Treatment Strategies for Ovarian Cancer: Brian Slomovitz, MD

June 4th 2025

Learnings From Key Clinical Trials in Ovarian Cancer

June 4th 2025

The Potential Impact of Investigational Therapies

June 3rd 2025

Relacorilant Plus Nab-Paclitaxel Improves Outcomes in Platinum-Resistant Ovarian Cancer: Brian Slomovitz, MD

June 1st 2025

Ovarian, Breast Cancer Disparities Highlight Need for Better Screening: CK Wang, MD

May 28th 2025

Single-Agent Vs Combination Regimens

May 28th 2025

Approaching Treatment Sequencing In Heavily Pretreated Patients

May 20th 2025

The Use of PARP Inhibitors in Ovarian Cancer

May 20th 2025

Earlier Introduction of Antibody-Drug Conjugates

May 16th 2025

Racial Disparities in Ovarian Cancer Could Increase as Trends Point to Access Barriers: CK Wang, MD

More News

1 expert in this video
May 13th 2025

The Role of Novel Targeted Therapies

Kathleen Moore, MD, MS
A panelist discusses how novel targeted therapies such as antibody-drug conjugates are rapidly evolving in gynecologic oncology, with multiple agents targeting different biomarkers in development, though optimal sequencing strategies remain to be determined.
1 expert in this video
May 13th 2025

Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer

Kathleen Moore, MD, MS
A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, recommending it as first-line therapy for folate receptor alpha–high tumors due to higher response rates when used earlier.
1 expert in this video
May 12th 2025

Improving Clinician Awareness and Adoption of Molecular Testing

Bradley J. Monk, MD, FACS, FACOG
A panelist discusses how guidelines from organizations like the National Comprehensive Cancer Network (NCCN) can improve clinician awareness and adoption of molecular testing in community oncology settings while acknowledging that some effective treatments work across patient populations without requiring biomarker stratification.
1 expert in this video
May 12th 2025

The Impact of Tumor Heterogeneity in Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG
A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, newer approaches like liquid biopsies can provide a more comprehensive genetic profile of the entire tumor burden.
FDA approval graphic | Image Credit: wladimir1804 - stock.adobe.com
May 9th 2025

FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC

Brooke McCormick
FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for patients with this condition.
1 expert in this video
May 5th 2025

Comprehensive Molecular Testing in Patients With Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG
A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for better education of health care providers and more affordable, widely available testing options.
1 expert in this video
May 5th 2025

Emerging Molecular Biomarkers in Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG
A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including microsatellite instability (MSI), tumor mutational burden (TMB), HER2, p53, KRAS, and CCNE amplification.
1 expert in this video
April 28th 2025

FRα Biomarker Testing in Patients With Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG
A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing the importance of comprehensive biomarker testing at diagnosis rather than piecemeal testing.
1 expert in this video
April 28th 2025

The Role of Guidelines on Molecular Testing in Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG
A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for treatment decisions, prognostic information, and family prevention strategies.
female infertility | Image Credit: © dizain-stock.adobe.com
April 27th 2025

No Definitive Link Found Between Female Infertility and Gynecological Cancer

Maggie L. Shaw
New research explores the complex relationship between female infertility and gynecological cancers, revealing minimal links and emphasizing the need for further studies.
BMI graphic | Image Credit: Vitalii Vodolazskyi - stock.adobe.com
April 22nd 2025

Overweight-to-Obese Trajectory in Adulthood May Raise Ovarian Cancer Risk

Brooke McCormick
Individuals who transition from overweight to obese during adulthood may face a higher ovarian cancer risk, highlighting the importance of tracking body fat changes.
CA-125 test | Image Credit: jarun011 - stock.adobe.com
April 17th 2025

Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays

Brooke McCormick
Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Patient taking survey | Image Credit: terovesalainen - stock.adobe.com
April 15th 2025

EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

Brooke McCormick
The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.
Ovarian cancer animation | Image Credit: Dr_Microbe - stock.adobe.com
April 9th 2025

Sociodemographic Factors Impact Cytoreductive Surgery Decisions in Advanced Ovarian Cancer

Brooke McCormick
Patients with advanced epithelial ovarian cancer who were non-Hispanic Black, older, had lower household income, resided in nonmetropolitan areas, and were unmarried had higher odds of refusing cytoreductive surgery.
Woman stepping on scale | Image Credit: Hunterframe - stock.adobe.com
April 3rd 2025

Obesity May Increase Surgical Complications in Epithelial Ovarian Cancer

Brooke McCormick
The most common surgical complications in obese patients with epithelial ovarian cancer (EOC) include wound infection, intestinal problems, and a higher 30-day readmission rate.
Woman affected by blurry vision | Image Credit: Prostock-studio - stock.adobe.com
March 25th 2025

Ocular Adverse Events From Mirvetuximab Soravtansine Not Associated With HRQoL Impact in FRα+ Ovarian Cancer

Brooke McCormick
New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) for patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.
Dr Toon Van Gorp
March 20th 2025

Dr Toon Van Gorp: Mirvetuximab Soravtansine Should Be Global Standard for FRα+ Ovarian Cancer

Brooke McCormick Toon Van Gorp, MD, PhD
Toon Van Gorp, MD, PhD, a MIRASOL trial investigator, emphasizes that the final analysis reinforces the efficacy of mirvetuximab soravtansine-gynx (Elahere; AbbVie) in patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.
Dr Toon Van Gorp
March 18th 2025

Final MIRASOL Trial Analysis Confirms Consistent Efficacy of Mirvetuximab Soravtansine

Brooke McCormick Toon Van Gorp, MD, PhD
The final analysis showed similar overall survival, progression-free survival, and objective response rates, with no new safety signals identified compared with the primary analysis.
Ovarian cancer awareness | Image Credit: Queenmoonlite Studio - stock.adobe.com
March 17th 2025

Updated MIRASOL Data Confirm Efficacy of Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

Brooke McCormick
The final data analysis confirmed that mirvetuximab soravtansine-gynx (Elahere; AbbVie) significantly improves progression-free survival, overall survival, and objective response in patients with folate receptor alpha-positive (FRα+) platinum-resistant ovarian cancer.
Dr Chun Chao
March 6th 2025

Navigating Future Public Health Emergencies With Pandemic Lessons on Ovarian Cancer

Brooke McCormick Chun Chao, PhD, MS
Optimizing telehealth during public health emergencies to minimize in-person appointments puts less burden on patients and may lead to better outcomes, according to Chun Chao, PhD, MS, of Kaiser Permanente Southern California.
Dr Chun Chao
March 3rd 2025

Stable Remission Rates Found in Insured Patients With Ovarian Cancer Amid COVID-19 Pandemic

Brooke McCormick Chun Chao, PhD, MS
These findings may not be generalizable to uninsured patients with ovarian cancer, who face unique barriers to care compared with insured patients.
Dr Chun Chao
February 27th 2025

Diving into the COVID-19 Pandemic’s Impact on Ovarian Cancer, Remission Rates

Brooke McCormick Chun Chao, PhD, MS
With the potential for future pandemics, Chun Chao, PhD, MS, emphasizes the importance of learning from the COVID-19 pandemic's impact on cancer care, particularly for patients with ovarian cancer.
COVID-19 pandemic illustration | Image Credit: James Thew - stock.adobe.com
February 20th 2025

Ovarian Cancer Remission Rates Remained Stable Before, After COVID-19 Pandemic

Brooke McCormick
The comparable rates of remission pre- and post-pandemic suggest that COVID-19 did not negatively impact the outcomes of patients with ovarian cancer.
Female patient drinking water and eating healthy | Image Credit: Viacheslav Yakobchuk - stock.adobe.com
February 18th 2025

Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status

Brooke McCormick
In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected overall survival but not progression-free survival.
Ovarian cancer illustration | Image Credit: tashatuvango - stock.adobe.com
February 12th 2025

High Prevalence of Sarcopenia Identified in Patients With Ovarian, Endometrial Cancer

Brooke McCormick
The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early screening and preventive measures for these populations.
Genetic testing illustration | Image Credit: Giovanni Cancemi - stock.adobe.com
February 5th 2025

Physician Gaps in Genetic Testing Knowledge May Impact Ovarian Cancer Care

Brooke McCormick
While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient access to genetic counseling.
Ovarian cancer awareness illustration | Image Credit: Queenmoonlite Studio - stock.adobe.com
February 3rd 2025

Olaparib Leads PARP Inhibitors in Boosting OS for Platinum-Sensitive Recurrent Ovarian Cancer

Brooke McCormick
While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.
Clinician holding box of niraparib | Image Credit: luchschenF - stock.adobe.com
January 28th 2025

Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases

Brooke McCormick
First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.
Ovarian cancer awareness illustration | Image Credit: Queenmoonlite Studio - stock.adobe.com
January 23rd 2025

Real-World Study Highlights PARP Inhibitor Challenges in Ovarian Cancer Care

Brooke McCormick
Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for enhanced strategies to optimize postrecurrence treatment.
Surgeon team performing an operation | Image Credit: Georgii - stock.adobe.com
January 21st 2025

Gynecologic Oncology Practices Evolve With Surgical De-Escalation Trends

Brooke McCormick
Researchers identified a 15-year shift toward surgical de-escalation in gynecologic oncology, marked by fewer surgical interventions, increased adoption of minimally invasive techniques, and a greater focus on fertility preservation and sentinel lymph node procedures.
1234567>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo